Infosys posts better than expected returns, but lowers guidance: Infosys announced a higher than expected 7% percent increase in net profits for the December quarter, but pared its revenue guidance for the entire FY17, saying that it expected to grow between 8.4% - 8.8%. The earlier guidance had ranged between 8% - 9%. The IT major may be attributing some downside risk to incoming President Trump, who has promised to cancel the H1B visa program and tax international goods and services.  

After months of swirling rumors on the possibilities of the future Tata Sons Chairman, the holding company named long-time Tata insider Natarajan Chandrasekaran - CEO of TCS - as the new Chairman. This is the kind of nomination unlikely to rock the boat or try to upend old rules, and Tata Sons clearly hopes to calm markets after the rocky exit of Cyrus Mistry. The questions on corporate governance and the control of the Tata Trusts have gone unanswered, as these issues are being challenged in various court cases. 

Stock in spotlight: Cadila Healthcare, which has reached an agreement with Upsher-Smith that allows it to market a generic version of Qudexy XR tablets in the US. 

Photo of the day: Siblings dressed as river goddesses at the Magh Mela in Allahabad. Rajesh Kumar Singh/AP